tbuckley/cabot-search huggingface dataset:
Protest against Our Quarantine Regulations.
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intensive Review of Internal Medicine
Authors: Alan R. Aronson
Journal: JAMA (1994)

<i>Intensive Review of Internal Medicine</i>(1993) is the fourth edition of a study course developed by the Department of Continuing Education of Harvard Medical School and the Department of Medicine of Brigham and Women's Hospital. I had the privilege of reviewing the third edition in 1988 forTHE JOURNAL. This has allowed me to compare as well as critique the program. The<i>Review</i>does everything it was designed to do and compares favorably with the 1988 edition. There are 40 audiocassettes with the authors of the sections in the book speaking, rather than professional speakers. The quality of the audio version is excellent and follows the printed material faithfully. In fact, that is the only criticism I could find with the course. The tapes are so precise that one is unable occasionally to follow the discussion as references are made to illustrations and diagrams. The printed material has 59 lectures
Weight and Diabetes
Authors: Sharon Parmet
Journal: JAMA (2008)

Weight and Diabetes Diabetes is a common disorder in which the body has difficulty controlling levels of sugar in the bloodstream.Normally, the hormone insulin made by the pancreas (an organ in the abdomen) regulates blood sugar levels.The bodies of individuals with type 1 diabetes, which usually starts by the early teen years, do not make enough insulin to control blood sugar, so they must receive insulin injections.The bodies of persons with type 2 diabetes are resistant to the effects of insulin.Type 2 diabetes, also known as "adult-onset" diabetes, usually develops in adulthood but can also occur in overweight children.Family history of diabetes and excess weight, especially weight carried around the middle, are strong risk factors for developing type 2 diabetes.Losing weight greatly reduces your chances for type 2 diabetes and can help bring your blood sugar under control if you already have type 2 diabetes.Type 2 diabetes can be treated with diet, exercise, and oral prescription medications but may require insulin shots.The June 18, 2008, issue of JAMA includes an article about an association between type 2 diabetes and depression.
SWEDEN
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus—Reply
Authors: Júlio C. Voltarelli
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Cardiac RKIP induces a beneficial β-adrenoceptor–dependent positive inotropy
Authors: Evelyn Schmid, Stefan Neef, Christopher Berlin, Angela Tomasovic, Katrin Kahlert, Peter Nordbeck, Katharina Deiss, Sabrina Denzinger, Sebastian Herrmann, Erich Wettwer, Markus Weidendorfer, Daniel Becker, Florian Schäfer, Nicole Wagner, Süleyman Ergün, Joachim P Schmitt, Hugo A Katus, Frank Weidemann, Ursula Ravens, Christoph Maack, Lutz Hein, Georg Ertl, Oliver J Müller, Lars S Maier, Martin J Lohse, Kristina Lorenz
Journal: Nature Medicine (2016)
Unfair Tests.
Authors: Dudley Tait
Journal: JAMA (1902)

San Francisco, Oct. 11, 1902. <h3>To the Editor:</h3> —In your editorial on "Unfair Tests," in the issue of October 4, you discuss the criticism by the<i>Pacific Medical Journal</i>of the questions in pathology submitted by the California State Board of Medical Examiners. In order that your deductions should have full value, it seems to me fair that a full knowledge of the truth of the facts in your premises should be given you. You suppose that the writer of the editorial in the<i>Pacific Medical Journal</i>is correct in stating that some were rejected for failure to answer the questions to which exception was taken—"Define cryoscopy," and "What are the characteristic lesions of Hanot's cirrhosis." First, as to the truth of this. The editor of the<i>Pacific Medical Journal</i>is dean of a recently organized medical school in San Francisco and president and manager of its board of trustees.
Spontaneous Closure of Interventricular Septal Defect: A New Observation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Onset heart rate criteria of microvolt-level T-wave alternans provides an additional prognostic value in nonischemic dilated cardiomyopathy Hidetsuna Kitamura, Yoshio Ohnishi, Kazumasa Adachi, Katsunori Okajima, Akihiko Ishida, Erdulfo J. Galeano F, Akihiro Yoshida, Mitsuhiro Yokoyama. Kobe University School of Medicine, First Department of Internal Medicine, Kobe, Japan
Journal: Journal of the American College of Cardiology (2001)
Membranous glomerulopathy and nephrotic syndrome after captopril therapy
Authors: B. C. Sturgill
Journal: JAMA (1983)

Membranous glomerulopathy and proteinuria have occurred in patients receiving captopril for hypertension. In this case of captopril-associated nephrotic syndrome, a pretreatment biopsy specimen showed normal histologic appearance and glomerular ultrastructure. A posttreatment biopsy specimen showed membranous glomerulopathy. It seems likely that captopril caused the membranous glomerulopathy. (<i>JAMA</i>1983;250:2343-2345)
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1961)

COMMITTEE ON MATERNAL AND PERINATAL WELFARE*Staphylococcal SepticemiaA twenty-eight-year-old gravida 3 with two previous cesarean sections underwent repeat section on schedule after a normal pregnancy. The temperature and other signs were normal except for a single reading of 101°F. on the fourth day. She was discharged the next day, but diarrhea developed, and she was readmitted to the hospital three days later, complaining of general abdominal pain, loose stools and dyspnea. There was moderate abdominal distention, with occasional bowel sounds. A Levin tube was passed, and an infusion containing 100,000 units of penicillin was started as well as 1 . . .
PTU-124 An External Validation Of The Hepatoma Arterial-embolisation Prognosis (hap) Score: The Liverpool Experience
Authors: O Noorullah, VP Lekharaju, IU Din, J Klcova, T Cross, J Evans, R Sturgess, D Palmer, E O’Grady, N Stern
Journal: Gut (2014)

<h3>Introduction</h3> Most Hepatocellular Carcinomas (HCCs) have palliative treatment. Trans-arterial embolisation (TAE) or chemoembolisation (TACE) are used with variable results. The HAP score was recently described to determine patients likely to benefit from TAE or TACE. We report our experience with TAE and TACE to assess whether the HAP score was valid for our cohort of patients. <h3>Methods</h3> Retrospective review of cases given TAE or TACE in Liverpool, UK (2006–2013). HAP score [1 point each for albumin &lt; 36 g/dl, AFP &gt; 400 ng/ml, Bilirubin &gt; 17 µmol/l, tumour diameter &gt; 7cm. HAP A = 0 points, B = 1, C = 2, D &gt;2]. Outcome recorded according to HAP score. <h3>Results</h3> 137 patients identified having received TAE/TACE with full data to complete HAP score. Mean age 69; 116 (84.7%) male. 78.8% AUH, 21.2% RLUH. HAP score A: 44 (32.1%); B: 40 (29.2%); C: 32 (23.4%); D: 21 (15.3%). Overall median survival 492 days (16 months). Median survival by HAP score, A: 492 days; B: 839 days; C 478 days; D 309 days. Log rank p &lt; 0.001. Survival at 1 year: A 62.8%; B 75%; C59.4%, D 28.6%. Survival at 2 years: A 29.5%, B 52.5%, C 37.5%, D 14.3%. HAP D patients had lower median survival (309 vs. 563 days; p &lt; 0.001) and 1 and 2 year survival (28.6 vs. 65.5%; p = 0.001 and 14.3 vs 39.7%; p = 0.021). <h3>Conclusion</h3> Patients with HAP score D due TACE have a relatively poor outcome in this external validation group. This should be considered when planning treatment or further trials. <h3>Reference</h3> Kadalayil <i>et al</i>. <i>Annals of Oncology</i> 2013 <h3>Disclosure of Interest</h3> None Declared.
Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.
Authors: Elizabeth J. Hovey, Paul L. De Souza, Gavin M. Marx, Phillip Parente, Tal Rapke, Andrew Hill, Antonino Bonaventura, Antonio Michele, Paul Stanley Craft, Ehtesham A. Abdi, Andrew R. Lloyd
Journal: Journal of Clinical Oncology (2012)

211 Background: Chemotherapy-induced fatigue is a common complaint for patients with cancer. We investigated whether modafinil, a psychostimulant, could reduce fatigue in patients on chemotherapy. Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel group study was conducted in patients with metastatic prostate or breast cancer suffering significant chemotherapy-related fatigue whilst undergoing docetaxel-based chemotherapy. Patients were enrolled at the start of their 3 rd or subsequent cycles of docetaxel which was continued for up to four further cycles (defined here as ‘treatment periods’). Patients were randomized 2:1 to receive modafinil 200mg daily or placebo for 15 days during each treatment period. Fatigue was evaluated by the MD Anderson Symptom Inventory (MDASI). The primary endpoint was MDASI area under the curve (AUC) during the first 7 days of study medication for the first two treatment periods (possible range 0-70). Other validated tools were used to record disturbances in sleep, mood and functional status. Results: Eighty-three patients (65 with prostate cancer) were randomized and received at least one dose of study medication. The number of grade 3 or 4 adverse events (AEs) was 16/55 (29.1%) in the modafinil group and 5/28 (17.9%) in the placebo group. The toxicity profile was largely consistent with docetaxel-based chemotherapy and with previously reported AEs associated with modafinil use in the community; 11 AEs were possibly related to docetaxel; 1 to modafinil and 9 to neither treatment. Conclusions: Managing chemotherapy-related fatigue remains a major challenge. Despite not reaching the primary endpoint, there was a consistent trend towards improvement of chemotherapy-related fatigue in the modafinil arm. Further studies are needed to better understand the clinical implications of these findings. Funding sanofi-aventis; Study ID NCT00917748 . [Table: see text]
American Journal of Cardiology, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renovascular hypertension secondary to arterial fibrodysplasia. Treatment by dilation using a Fogarty balloon
Authors: W. S. Houck
Journal: JAMA (1979)

RENOVASCULAR hypertension is most commonly caused by atherosclerosis, and the proximal renal artery is usually involved in this process. Approximately 40% of renal hypertension is secondary to fibromuscular hyperplasia.<sup>1</sup>This disease process primarily affects the distal main renal artery, but in approximately 24% of the cases, the primary and secondary branches of the renal artery are involved.<sup>1</sup>In these latter situations, the disease is not amenable to the usual surgical procedure of bypass vein grafting. We recently cared for a 49-year-old woman with renovascular hypertension secondary to fibromuscular disease. This patient's problem was successfully treated by renal artery dilation using a No. 4 Fogarty balloon. <h3>Report of a Case</h3> A 49-year-old woman had long-standing hypertension. Her blood pressure (BP) was poorly controlled with hydrazaline hydrochloride, methyldopa, and methyclothiazide. She had noted the onset of severe headaches that required medication. A recent intravenous pyelogram (IVP) showed a differentiation in
Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Authors: R. Marcus
Journal: Endocrine Reviews (2002)

Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective of this review is to summarize the results from clinical trials that have fracture as an endpoint and to discuss the factors in study design and populations that can affect the interpretation of the results. Although there are numerous observational studies suggesting that estrogen and hormone replacement therapies may reduce the risk of vertebral and nonvertebral fractures, there is no large, prospective, randomized, placebo-controlled, double-blind clinical trial demonstrating fracture efficacy. The effects of raloxifene, alendronate, risedronate, and salmon calcitonin on increasing bone mineral density (BMD) and decreasing fracture risk have been shown in randomized, placebo-controlled, double-blind clinical trials of postmenopausal women with osteoporosis. Although the increases in lumbar spine BMD vary greatly in these trials, the decrease in relative risk of vertebral fractures is similar among therapies. However, nonvertebral fracture efficacy has not been consistently demonstrated. Combined administration of two antiresorptive therapies results in greater BMD increases, but the effects on fracture risk are unknown. Direct comparisons of clinical trial results should be considered carefully, given the differences in study design and populations. Differences in study design that may influence the efficacy of fracture risk reduction include calcium and vitamin D supplementation, primary fracture endpoints, definition of vertebral deformity or fracture, discontinuation rates, and statistical power. Factors in the study population that may influence fracture efficacy include the age of the population and the proportion of subjects with prevalent fractures. The use of surrogate endpoints such as BMD to predict fracture risk should be approached with caution, as the relationship between BMD changes and fracture risk reduction with antiresorptive therapies is uncertain. Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis.
Abstract 4235: Phosphorylation of Serine 861 in the ECT2 guanine nucleotide exchange factor activates Rho family GTPases and is a biomarker for several tumor types
Authors: Dunrui Wang, Xiaolan Qian, Sarah Eng, Shivani Nellore, Alex G. Papageorge, Douglas R. Lowy
Journal: Cancer Research (2019)

Abstract The Rho family of GTPases, which cycle between inactive GDP-bound and active GTP-bound states, have high activity in many cancers. One mechanism for their activation is by guanine nucleotide exchange factors (GEFs), which stimulate the replacement of GDP-bound Rho with GTP-bound Rho. In this study, we report phosphorylation of Epithelial Cell Transforming 2 (ECT2), which is a Rho family-specific GEF, is a biomarker in several tumor types, based on bioinformatic analysis and biological assays. Our analysis of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) database found that Serine 861 (S861) in ECT2 is more highly phosphorylated in several tumor types compared to its phosphorylation in the relevant normal tissue. S861 phosphorylation is 2.1-fold and 2.4-fold higher in colon cancer and ovarian cancer, respectively, and high S861 phosphorylation in breast cancer is correlated with a poorer prognosis. Phosphorylation of S861 is especially high in triple-negative breast cancer, as it is 2.3-fold higher in this type compared with the other types of breast cancer. Increased phosphorylation of S861 is associated increased ECT2 mRNA and protein levels in colon cancer and breast cancer. In experimental studies, siRNA knockdown of endogenous ECT2 in two triple-negative breast cancer lines resulted in lower levels of RhoA-GTP, Rac-GTP, and Cdc42-GTP, and led to reduced cell migration, cell proliferation, and anchorage-independent growth, suggesting that ECT2 is a key regulator of cellular signaling and oncogenic growth in the triple-negative lines. Conversely, ectopic expression of wild-type ECT2 induced increased levels of RhoA-GTP, Rac-GTP, and Cdc42-GTP and promoted migration, proliferation, and anchorage-independent growth. Compared with wild type ECT2, ectopic expression of ECT2 carrying a phospho-defective (S861A) or phospho-mimic (S861D) mutation, respectively, reduced or enhanced ECT2 GEF and biological activities. Our results indicate that phosphorylation of S861 enhances the pro-oncogenic activity of ECT2, which is correlated with the increased phosphorylation of S861 in the three cancer types, the increased expression of ECT2 in two of these cancer types, and the prognostic significance of S861 phosphorylation in breast cancer. * Dunrui Wang and Xiaolan Qian are Equal contributors Citation Format: Dunrui Wang, Xiaolan Qian, Sarah Eng, Shivani Nellore, Alex G. Papageorge, Douglas R. Lowy. Phosphorylation of Serine 861 in the ECT2 guanine nucleotide exchange factor activates Rho family GTPases and is a biomarker for several tumor types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4235.
SMILE A WHILE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal